Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Volcano gets to Crux of $300m peripheral embolism market with $36m acquisition

This article was originally published in Clinica

Executive Summary

Volcano, which specialises in devices for facilitating endovascular procedures, has entered the peripheral vascular market by agreeing to acquire privately-held Crux Biomedical for $36 million in cash. Volcano (San Diego, California) will also pay up to $3.1 million in transaction expenses, and a milestone payment of $3.0 million upon US FDA clearance of a 510(k) application submitted by Volcano on or before June 30 2013, for a retrieval device currently being developed by Crux.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts